Immunomedics, Inc.

Company: Immunomedics, Inc.

Class Period: August 23, 2018 — December 20, 2018

Court: U.S.D.C. - District of New Jersey

Deadline: February 25, 2019

Kaskela Law LLC announces that a class action lawsuit has been filed against Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ: IMMU) on behalf of investors who purchased the Company’s common stock between August 23, 2018 and December 20, 2018, inclusive (the “Class Period”).

The class action complaint alleges that Immunomedics misled investors during the Class Period by stating in its SEC filings that “the FDA generally will issue a notice on Form 483 if it finds issues with respect to its inspections” without disclosing to investors the fact that, between August 6, 2018, and August 14, 2018, the FDA cited Immunomedics for a host of violations observed at its Morris Plains, New Jersey, drug substance manufacturing facility. These violations included manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.

On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.”  According to the article, “[t]he FDA cited Immunomedics for a host of violations – including its handling of a data integrity breach – observed at its Morris Plains, New Jersey, drug substance manufacturing facility between August 6 and 14.”  The article reported that the breach included “manipulated bioburden samples, misrepresentation of an integrity test procedure in the batch record, and backdating of batch records, such as dates of analytical results.”  Following this report, shares of Immunomedics’ stock declined to $17.86 per share.

Subsequently, on December 20, 2018, Favus Institutional Research issued a Report (the “Favus Report”) further detailing the data integrity breach.  Following the Favus Report, shares of the Company’s stock declined $3.47 per share, or nearly 20% in value, to close on December 20, 2018 at $14.17 per share, on heavy trading volume.

IMPORTANT DEADLINE:  Investors who purchased Immunomedics’s common stock during the Class Period may, no later than February 25, 2019, seek to be appointed as a lead plaintiff representative of the class.

Immunomedics investors are encouraged to contact Kaskela Law LLC at (888) 715 – 1740 to discuss their legal rights and options, or complete the form on this page to request additional information about the action.

Submit Your Information

  • This field is for validation purposes and should be left unchanged.